Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1527 articles about Takeda
-
AMAG Pharmaceuticals, Inc. Gets Initial EU Nod, Potentially Bagging a $30 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd.
4/23/2012
-
Takeda Pharmaceutical Co. Ltd. and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers
4/17/2012
-
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Announce Centers for Medicare and Medicaid Services Has Assigned a Q-Code for OMONTYS® (Peginesatide) Injection
4/13/2012
-
Nycomed, a Takeda, Launches Omnaris(R) Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
3/14/2012
-
Takeda Pharmaceutical Co. Ltd. Hid Actos Adverse Effects From Regulators, Suit Says
3/8/2012
-
Takeda Pharmaceutical Co. Ltd.'s TAK-875 Fights Diabetes as Well as Older Generic Drug in a Study
2/27/2012
-
Takeda Pharmaceutical Co. Ltd.'s Inflammatory Bowel Disease Drug Meets Phase 3 Targets
2/21/2012
-
GlaxoSmithKline, Takeda Pharmaceutical Co. Ltd. Unlikely to Build In-House Diagnostic Units
2/13/2012
-
Ex-Takeda Pharmaceutical Co. Ltd. Exec Committed Insider Trading, SEC Claims
2/10/2012
-
Takeda Pharmaceutical Co. Ltd. Sets Up China Division to Supervise Clinical Trials
2/9/2012
-
Takeda Pharmaceutical Co. Ltd. Release: EDARBYCLOR (Azilsartan Medoxomil and Chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
2/6/2012
-
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd.'s Bowel Dysfunction Drug Succeeds in Second Phase III Study
2/2/2012
-
Takeda Pharmaceutical Co. Ltd. Wins FDA Approval for New Way to Adminster Velcade to Patients
1/25/2012
-
Takeda Pharmaceuticals Plans to Reduce Europe, U.S. Workforce by 2,800 Jobs
1/19/2012
-
Takeda Pharmaceutical Co. Ltd. Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
1/18/2012
-
Takeda Pharmaceutical Co. Ltd. to Acquire Privately-held Intellikine, Inc. for Up to $310 Million Cash
12/21/2011
-
FDA Approves Takeda Pharmaceutical Co. Ltd.'s EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
12/21/2011
-
Takeda Pharmaceutical Co. Ltd. and Affymax, Inc. Provide Update on Peginesatide Commercialization Rights in Japan
12/16/2011
-
Takeda Pharmaceutical Co. Ltd. Drug Cuts Myeloma Death Risk in 5-Year Study
12/14/2011
-
AMAG Pharmaceuticals, Inc., Takeda Pharmaceutical Co. Ltd.: Health Canada Approves Feraheme® (ferumoxytol) to Treat Iron Deficiency Anemia in Adults with Chronic Kidney Disease
12/12/2011